Clinical Cardiology Alert – September 1, 2010
September 1, 2010
View Issues
-
Eptifibatide and Abciximab Equally Effective in Primary PCI
Platelet aggregation is an important pathophysiological step in the development of myocardial infarction (MI), and intensive anti-platelet therapy has become a cornerstone of therapy in patients presenting with MI. -
Viability Studies Before Selecting Revascularization?
Although ischemic left ventricular (LV) dysfunction is an indication for revascularization, little is known about the long-term benefits of revascularization and the value of viability studies. -
Stent Thrombosis Post Non-cardiac Surgery
There is considerable concern regarding in-stent thrombosis of drug-eluting stents (DES) when aspirin and clopidogrel are stopped for non-cardiac surgery (NCS), but a paucity of data. -
Chest Compression-only CPR
The dispatcher-assisted resuscitation trial (DART) tested the hypothesis that 911 dispatcher instructions to provide chest compressions only would be superior to similar instructions that included both chest compressions and rescue breathing. -
Initial Experience with Wearable Cardioverter-Defibrillator
The wearable cardioverter-defibrillator (WCD) is a totally external system that can monitor a patient's cardiac rhythm and automatically treat episodes of ventricular tachycardia (VT) and ventricular fibrillation (VF) when they are detected. -
Exercise Pulmonary Hypertension in MR
Current guidelines recommend mitral-valve surgery for severe organic mitral regurgitation in asymptomatic patients if exercise pulmonary hypertension (PASP > 60 mmHg) is demonstrated. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.